Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California

 

Recent News and Articles on the Keywords: glucose level + using thiazolidinediones + exenatide  Related to the article below (Last Update: 7/8/2008)


ChattahBox
ADA: No Efficacy or Safety Sacrifice with Weekly Exenatide (Byetta)
MedPage Today, NJ - Jun 11, 2008
Not only did weekly exenatide lead to greater declines in A1C levels, but in fasting plasma glucose as well. By the end of 30 weeks, patients treated weekly ...
After One Year, Type 2 Diabetes Patients Taking Exenatide Once ... istockAnalyst.com
Monotherapy BYETTA(R) (exenatide) Injection Study Results ... Lifescience-online
ADA: Exenatide Benefit Not Always Sustained in Type 2 Diabetes MedPage Today
all 200 news articles »  LLY - AMLN - ALKS
Incyte's Selective Oral Inhibitor of 11beta-HSD1 Demonstrates ...
WELT ONLINE, Germany - Jun 9, 2008
Unlike the hormone insulin, which is produced by beta-cells in the pancreas and maintains normal blood glucose levels, cortisol elevates blood glucose ...INCY
ACCORD Results Show Increased Mortality With Aggressive Treatment
DG News - Jun 9, 2008
BETHESDA, Md -- June 9, 2008 -- Intensively targeting blood sugar to near-normal levels in adults with type 2 diabetes at very high risk for heart attack ...

In order to show you the most relevant results, we have omitted some entries very similar to the 3 already displayed.
If you like, you can repeat the search with the omitted results included.

Source: Google News

Exenatide versus Insulin Glargine in Patients with Suboptimally Controlled Type 2 Diabetes: A … -
RJ Heine, LF Van Gaal, D Johns, MJ Mihm, MH Widel, … - Annals of Internal Medicine, 2005 - annals.highwire.org
... areas under the curve (AUCs) for glucose levels from 0 ... as areas under the excursion)
by using the trapezoidal ... AUC, then subtracting the time-0 level across the ...

A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes … -
MA Nauck, S Duran, D Kim, D Johns, J Northrup, A … - Diabetologia, 2007 - Springer
... within 3 months; or (3) had been treated with insulin, thiazolidinediones,
alpha-glucosidase ... Fasting glucose levels were measured using the hexokinase ...

The Effect of Adding Exenatide to a Thiazolidinedione in Suboptimally Controlled Type 2 Diabetes: A … -
B Zinman, BJ Hoogwerf, S Duran Garcia, DR Milton, … - Annals of Internal Medicine, 2007 - annals.highwire.org
... Insulin-sensitizing thiazolidinediones (TZDs) are widely used for ... Using the PROC
MIXED analysis in SAS ... body weight, fasting serum glucose level, HOMA of ? ...

Inhaled Insulin Improves Glycemic Control When Substituted for or Added to Oral Combination Therapy … -
J Rosenstock, B Zinman, LJ Murphy, SC Clement, P … - Annals of Internal Medicine, 2005 - annals.highwire.org
... We measured fasting plasma glucose levels at weeks ?4, ?1, 0, and ... We performed liver
function tests monthly in patients who were using thiazolidinediones. ...

Exenatide: A Novel Incretin Mimetic Agent for Treating Type 2 Diabetes Mellitus. -
S Lam, CGP PharmD, S See, B PharmD - Cardiology in Review, 2006 - cardiologyinreview.com
... of insulin in response to elevated blood glucose level, inhibiting the rise of glucagon
level after meals ... Of concern, some physicians are using the drug for ...

Exenatide. -
GM Keating - Drugs, 2005 - drugs.adisonline.com
... as metformin, sulfonylureas, meglitinides, thiazolidinediones and ?-glucosidase ... the
ITT population using a last ... in postprandial plasma glucose levels and the ...

Exploring the Substitution of Exenatide for Insulin in Patients With Type 2 Diabetes Treated With … -
SN Davis, D Johns, D Maggs, H Xu, JH Northrup, RG … - Diabetes Care, 2007 - Am Diabetes Assoc
... by total exposure) was calculated using two criteria ... a diminished capacity to exert
a glucose-lowering effect ... pretreatment fasting C-peptide levels, were taking ...

Exenatide -
A Barnett - Expert Opin. Pharmacother., 2007 - Expert Opinion
... interventions, metformin and thiazolidinediones would receive as ... has been assessed
using a mathematical ... of different ambient glucose levels among treatments ...

Day-long subcutaneous infusion of exenatide lowers glycemia in patients with type 2 diabetes -
K Taylor, D Kim, LL Nielsen, M Aisporna, AD Baron, … - Horm Metab Res, 2005 - thieme-connect.com
... of metformin and one of the thiazolidinediones. ... descriptively and analyzed using
mixed effect ... after dosing commenced, plasma glucose levels were significantly ...

Exenatide: A New Option for the Treatment of Type 2 Diabetes -
BK Yoo, DM Triller, DJ Yoo - The Annals of Pharmacotherapy, 2006 - Harvey Whitney Books
... controlled clinical study by using the plasma ... recipients had significantly lower
glucose values preprandially ... but significantly higher levels postprandially. ...

Source: Google Scholar
 
 

Exenatide reduces blood glucose levels when added to patients using a thiazolidinedione

 
 
A study showed that Exenatide ( Byetta ) injection lowered blood glucose levels for people with type 2 diabetes who had not achieved target blood glucose levels despite the use of a thiazolidinedione with or without Metformin.

Patients using Exenatide showed improvements in three important measures of blood glucose control: fasting blood glucose, postprandial blood glucose and hemoglobin A1C ( A1C ), which improved by approximately 0.9 percent compared to the control group.
Sixty-two percent of study participants using Exenatide who completed the full study reached target A1C of 7 percent or less.

Exenatide treatment also resulted in a reduction in average body weight.
Exenatide -treated patients lost an average of approximately three pounds of body weight, while those treated with placebo lost on average approximately one- half pound.

A total of 233 patients with elevated A1C in spite of oral diabetes therapy were involved in the randomized, placebo-controlled, parallel, double-blind trial for 16 weeks.
The trial was designed to determine if Exenatide can be used safely and effectively as adjunctive therapy to a thiazolidinedione alone ( about 20 percent ) or with a thiazolidinedione and Metformin ( about 80 percent ), for people with type 2 diabetes.
Study participants were randomized into either of two treatments: the first group received a fixed dose of Exenatide ( 5 micrograms twice-a-day for first four weeks, then 10 micrograms twice-a-day for remainder of study ) in conjunction with a thiazolidinedione, with or without Metformin, and the second group received placebo with a thiazolidinedione, again with or without Metformin.
The average A1C at baseline was 7.9 percent.

Key findings

A1C reduction:

At the end of the study, patients on Exenatide experienced an average reduction in A1C of 0.8 percent from baseline compared to an increase of 0.1 percent in the control group.

Of patients completing the full study, 62 percent treated with Exenatide as a combination therapy achieved an A1C of 7 percent or less, compared to approximately 16 percent in the control group.

Glucose measurements:

Patients treated with Exenatide had average fasting glucose, measured before breakfast, that was 27 mg/dL lower than the control group.

As measured by 7-point glucose monitoring, Exenatide significantly reduced average 2-hour post-meal glucose surges following breakfast and dinner by 34 mg/dL from baseline.

7-point glucose monitoring throughout the day demonstrated a significant reduction in average glucose concentrations in patients receiving Exenatide.

Weight change:

Patients in the Exenatide arm showed an average weight reduction of 3.3 pounds compared with an average weight reduction of 0.4 pounds during treatment in the control arm.

Hypoglycemia:

Rates of mild and moderate hypoglycemia were similar between the Exenatide and placebo treatments. No severe hypoglycemia was reported.

Other adverse events:

The most common adverse event was mild to moderate nausea reported by approximately 40 percent of the patients in the Exenatide group, compared to 15 percent of patients receiving placebo.

Exenatide is the first incretin mimetic, a class of drugs for the treatment of type 2 diabetes. Exenatide exhibits many of the same effects as the human incretin hormone glucagon-like peptide-1 ( GLP-1 ).
GLP-1, secreted in response to food intake, has multiple effects on the intestine, liver, pancreas and brain that work in concert to regulate blood glucose.

Source: Eli Lilly, 2006
 
 
 
Google
Web www.iconocast.com
 
 
 

 

Continue News With: News3 ; News4 ; News5 ; News6 ; News7 ; News8 ; News9 ; News9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services. Home

 © 2002-2006

Keywords::

Contact Iconocast

Home Page